SCM
INSY

Sterling Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Sterling Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,848
Closed -$225K – 1020
2015
Q4 		$225K Buy
+7,848
New +$217K ﹤0.01% 918

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Sterling Capital Management's INSY Position: Q1 2016 in Review

Sterling Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2016, closing a stake of 7,848 shares — an estimated $225K sold.

Sterling Capital Management first reported a position in INSY in Q4 2015 and held it in 1 quarter. The position peaked at $225K in Q4 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q1 2016.

  • Sterling Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Sterling Capital Management sold 7,848 Insys Therapeutics, Inc. shares in Q1 2016, an estimated $225K.
  • Sterling Capital Management first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Sterling Capital Management's Insys Therapeutics, Inc. position peaked at $225K in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2016.

Based on Sterling Capital Management's 13F filing for Q1 2016, filed 17 May 2016.